Human Papillomavirus Market: By Type (Tetravalent, Bivalent, Polyvalent, and Others), By Disease Indication (Cervical Cancer, Anal Cancer, Vulvar & Vaginal Cancer, Penile Cancer, Oropharyngeal Cancer, and Others), By End User (Hospitals & Retail Pharmacies, Government Suppliers, and Others) and Geography  

Human Papillomavirus Market size was valued at USD 5,485.2 million in 2023 and is poised to grow at a significant CAGR of 12.7% over 2024-2030. Human papillomavirus (HPV) infection is a leading cause of secondary malignancies in those who have survived cancer in childhood, especially cervical and anal tumors (HPV). However, HPV vaccination can prevent secondary malignancies in young cancer survivors, and it efficiently avoids the infections that contribute to the cancers.

The increasing vaccine supply by international organizations such as UNICEF and WHO is driving the global human papillomavirus market growth. For instance, during the Global Vaccine Summit, GSK, Merck, and other international market players promised to provide a significant supply of vaccine doses to increase immunization against the disease in June 2020. Also, the highly efficient human papillomavirus vaccines drive global market growth. Moreover, the increasing prevalence of various types of cancer, especially cervical cancer, is anticipated to increase the sales of the Human Papillomavirus Vaccine. It is expected to follow the human papillomavirus market trend in the forecasted years. Also, the global market players are positively influencing the global human papillomavirus market growth through mergers, collaborations, and new product launches in this sector.

Based on the disease indication, the global market is segmented into cervical cancer, anal cancer, vulvar & vaginal cancer, penile cancer, oropharyngeal cancer, and others. cervical cancer treatment is holding the major human papillomavirus market revenue in 2022 and is expected to maintain its growth in upcoming years. However, limited product offerings by manufacturers may hamper the global human papillomavirus market growth. Geographically, Asia Specific held the major market share in the global human papillomavirus market and is expected to dominate the global market in the forecasted years.

Human Papillomavirus Market Key Developments:

• In Sept 2022, The Central government launched India's first vaccine against cervical cancer. The quadrivalent Human Papillomavirus vaccine (HPV) has been developed by the Serum Institute of India (SII) and the Department of Biotechnology (DBT).
• In Sept 2022, Roche announced the launch of a human papillomavirus (HPV) self-sampling solution in countries accepting the CE mark, expanding access to HPV screening options by enabling patients to collect their samples.